HomeFile

File

View Category
Antiplatelet

ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding

Ticagrelor seems as safe as clopidogrel in patients undergoing ST elevation MI treated with fibrinolytics, at least in terms...
solaci -
Learn More
Structural heart disease

Reverse Myocardial Remodeling Following Valve Replacement

After aortic valve replacement, focal fibrosis does not resolve, but diffuse fibrosis and cell hypertrophy regress. As...
solaci -
Learn More
Chronic Ischemic cardiopathy

ACC 2018 | DEFINE-FLAIR Sub-Analysis: iFR More Comfortable, Faster, and Much Cheaper

Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using...
solaci -
Learn More
Aorta

What’s New in the European Guidelines on Peripheral Arterial Disease

Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease...
solaci -
Learn More
Other

ACC 2018 | Echocardiographic Data Help Better Choose Patients for Patent Foramen Ovale Closure

A new randomized controlled trial of patients who underwent patent foramen ovale (PFO) closure in cryptogenic stroke...
solaci -
Learn More
Coronary disease

ACC 2018 | COMBO: New Stent with Thin Struts and Pro-Healing Membrane

The new COMBO stent, comprised of thin struts plus a bioengineered layer of endothelial progenitor cells, is...
solaci -
Learn More
STRUCTURAL HEART DISEASE

NOTION: 5-Year Outcomes of TAVR vs. Surgery in Low-Risk Patients are Promising

At 5 years, there were no differences in all-cause death, stroke, acute myocardial infarction, or all of these...
solaci -
Learn More
Structural heart disease

Permanent Pacemaker: still TAVR’s Aquila’s Heel

TAVR has shown benefits in high risk patients (prohibitive) and in intermediate risk patients, but the need for permanent...
solaci -
Learn More